Alzheimer’s Disease (AD) represents a major and rapidly growing burden to the healthcare ecosystem. A growing body of evidence indicates that cognitive, behavioral, sensory, and motor changes may precede clinical manifestations of AD by several years. Existing tests designed to diagnose neurodegenerative diseases, while well-validated, are often less effective in detecting deviations from normal cognitive decline trajectory in the earliest stages of the disease. In the quest for gold standards for AD assessment, there is a growing interest in the identification of readily accessible digital biomarkers, which harness advances in consumer grade mobile and wearable technologies. Topics examined include a review of existing early clinical manifestations of AD and a path to the respective sensor and mobile/wearable device usage to acquire domain-centric data towards objective, high frequency and passive digital phenotyping.
CITATION STYLE
Kourtis, L. C., Regele, O. B., Wright, J. M., & Jones, G. B. (2019, December 1). Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity. Npj Digital Medicine. Nature Publishing Group. https://doi.org/10.1038/s41746-019-0084-2
Mendeley helps you to discover research relevant for your work.